期刊
CANCER RESEARCH
卷 82, 期 7, 页码 1321-1339出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-21-2576
关键词
Ligand-independent activation; Epigenetic reprogramming; Secondary transactivation; Gap junction
类别
资金
- Breast Cancer Research Foundation
- Susan G. Komen Scholar awards [SAC110021, SAC170078, SAC160073]
- Metastatic Breast Cancer Network Foundation
- NCI [R01CA221303, F30CA203154, F30CA250167]
- Department of Defense Breast Cancer Research Program [W81XWH1910434, W81XWH1910499]
- Fashion Footwear Association of New York
- Canney Foundation
- ME Foundation
- Penguins Alumni Foundation
- Pennsylvania Breast Cancer Coalition
- Shear Family Foundation
- John S. Lazo Cancer Pharmacology Fellowship
- Department of Defense Breakthrough Fellowship Award [BC160764]
- NIH Pathway to Independence Award [K99CA237736]
- NIH [P30CA047904]
- Magee-Womens Research Institute and Foundation
- Nicole Meloche Foundation
- U.S. Department of Defense (DOD) [W81XWH1910434, W81XWH1910499] Funding Source: U.S. Department of Defense (DOD)
- CDMRP [917303, BC160764] Funding Source: Federal RePORTER
This study demonstrated the potential role of ESR1 mutations in distant recurrence of breast cancer. Through transcriptomic profiling and functional experiments, it was shown that ESR1 mutations altered the cell adhesive gene network, leading to enhanced cell-cell contacts and decreased cell-extracellular matrix adhesion. Additionally, ESR1-mutant cells formed larger and more compact multicellular circulating tumor cell clusters in vivo, and ESR1 mutations were associated with enrichment of circulating tumor cell clusters in metastatic breast cancer patients.
Constitutively active estrogen receptor alpha (ER/ESR1) mutations have been identified in approximately one-third of ER+ metastatic breast cancers. Although these mutations are known as mediators of endocrine resistance, their potential role in promoting metastatic disease has not yet been mechanistically addressed. In this study, we show the presence of ESR1 mutations exclusively in distant but not local recurrences in five independent breast cancer cohorts. In concordance with transcriptomic profiling of ESR1-mutant tumors, genome-edited ESR1 Y537S and D538G-mutant cell models exhibited a reprogrammed cell adhesive gene network via alterations in desmosome/gap junction genes and the TIMP3/MMP axis, which functionally conferred enhanced cell-cell contacts while decreasing cell-extracellular matrix adhesion. In vivo studies showed ESR1-mutant cells were associated with larger multicellular circulating tumor cell (CTC) clusters with increased compactness compared with ESR1 wild-type CTCs. These preclinical findings translated to clinical observations, where CTC clusters were enriched in patients with ESR1-mutated metastatic breast cancer. Conversely, context dependent migratory phenotypes revealed cotargeting of Wnt and ER as a vulnerability in a D538G cell model. Mechanistically, mutant ESR1 exhibited noncanonical regulation of several metastatic pathways, including secondary transcriptional regulation and de novo FOXA1-driven chromatin remodeling. Collectively, these data provide evidence for ESR1 mutation-modulated metastasis and suggest future therapeutic strategies for targeting ESR1-mutant breast cancer. Significance: Context- and allele-dependent transcriptome and cistrome reprogramming in mutant ESR1 cell models elicit diverse metastatic phenotypes related to cell adhesion and migration, which can be pharmacologically targeted in metastatic breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据